NCT03717948 is a NA clinical trial of BFR Exercise in Mitochondrial Biogenesis, sponsored by Queen's University.

Who is sponsoring NCT03717948?

NCT03717948 is sponsored by Queen's University.

What drugs are being tested in NCT03717948?

Interventions in NCT03717948: BFR Exercise, CTL Exercise.

What condition does NCT03717948 study?

NCT03717948 studies Mitochondrial Biogenesis.

Is NCT03717948 still recruiting?

NCT03717948 is currently completed. Last updated 15 July 2019.

Last reviewed 2019-07-15 · How we verify

NCT03717948

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Examining the Impact of Blood Flow Restricted Aerobic Exercise on PGC-1α mRNA Expression in Young Healthy Males

Completed NA Last updated 15 July 2019

What this trial tests

NA trial testing BFR Exercise in Mitochondrial Biogenesis in 13 participants. Completed in 28 January 2019.

Timeline

1 October 2018

Primary endpoint
28 January 2019

28 January 2019

Quick facts

Lead sponsor	Queen's University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	basic science
Enrollment	13
Start date	1 October 2018
Primary completion	28 January 2019
Estimated completion	28 January 2019
Sites	1 location across Canada

Drugs / interventions tested

BFR Exercise
CTL Exercise

Conditions studied

Mitochondrial Biogenesis — all drugs for Mitochondrial Biogenesis →

Sponsor

Queen's University

Who can join

Adults 18 to 30, male only, with Mitochondrial Biogenesis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This crossover study investigates the effects of restricting arterial blood flow during cycling exercise on PGC-1α and its upstream signalling pathways. In a randomized order, participants will exercise once for 30 minutes with restricted blood flow and then will exercise once for 30 minutes with no blood flow restriction.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Queen's University trials

Trials by the same sponsor.

NCT07526103 — Developing a Colonoscopy Preparation Protocol for Patients With Diabetes · NA · not yet recruiting
NCT07456670 — Caffeine for Infants Born at 28 to 34 Weeks Receiving Respiratory Support · Phase 2 · not yet recruiting
NCT06794723 — A Probiotic Based Intervention in Pregnancies Complicated by GDM · Phase 2 · not yet recruiting
NCT07030426 — Vaginal Estrogen for Improvement of Outcomes Following Pelvic Organ Prolapse Surgery · Phase 3 · not yet recruiting
NCT07036653 — Bone Enhanced Ultrasound (BEUS) Data Library Development Project · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03717948 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Queen's University
Last refreshed: 15 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03717948.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing